U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Title of Security (Instr. 3)	2. Transaction Date (mm/dd/yy) 7/15/02	Code (Instr. 8) Code V	Disposed of (D (Instr. 3, 4 a Amount	(A) or (D)	Price	Beneficially Owned at End of Month (Instr. 3 and 4) 2,770,465	Direct (D) or Indirect (I) (Instr.4)	
1. Title of Security (Instr. 3)	Transaction Date (mm/dd/yy)	Transaction Code (Instr. 8) Code V	Disposed of (D (Instr. 3, 4 a Amount	(A) (C) (D)	Price	Beneficially - Owned at End of Month (Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr.4)	Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	Transaction Date (mm/dd/yy)	Transaction Code (Instr. 8) Code V	Disposed of (D (Instr. 3, 4 a	nd 5) (A) or		Beneficially - Owned at End of Month (Instr. 3	Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership
		Transaction	Disposed of (D (Instr. 3, 4 a	ınd 5)		Beneficially	Direct	Nature of
			4. Securities Acquir Disposed of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially	6. Owner- ship Form: Direct	7. Nature of
Table I Non-Deriva	ative Securities Acc Beneficially Owned	quired, Dispos	ed of,					
	ief Scientist Office	er						
(Check all applicable) [X] Director [X] Officer (give title b	[>	(] 10% Owne] Other (s	r pecify below)					
======================================			========	:=				
======================================		========	========	=				
September 23, 2002								
======================================	:=======	-=======	========	:=				
3. IRS or Social Security Number	of Reporting Perso	on (Voluntary)						
GeneMax Corp. "GMXX" ===================================	:========:	========	=========	:=				
======================================		========	========	:=				
(City) (State) (Zip)								
Surrey, British Columbia Canada								
12596 23rd Avenue								
(Last) (First) (Middle)								

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly ${\sf Constant}$

^{*} See attachment A

^{**} See attachment B

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of	2. Conver- sion of Exer- cise Price of Deriv-	3. Trans- action Date	4. Trans- action Code (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of(D) (Instr. 3,	Expirati	ion Date Day/Year)	7. Title and of Underl Securitie (Instr. 3	lying es 3 and 4)	8. Price of Deriv- ative Secur-	9. Number of Deriv- ative Secur- ities Bene- ficially Owned at End of	10. Owner-ship of Deriv- ative Secur- ity: Direct (D) or In- direct	11. Nature of In- direct Bene- ficial Owner-
Derivative Security	ative Secur-	(Month/ Day/	8)	4 and 5)	Date Exer-	Expira- tion		Number of	ity (Instr.	Month	(I) (Instr.	ship
(Instr. 3)	ity	Year)	Code V	(A) (D)	cisable	Date	Title	Shares	5)	4)	4)	4)
Not applicable												
Explanation of F	esponses:	=======	======		=======	=======		======	======		======	======

/s/ Dr. Wilfred Jefferies	September 23, 2002
**Signature of Reporting Person	Date

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedures.

^{*} Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

ATTACHMENT A TO FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FOR WILFRED JEFFERIES

On May 9, 2002, effective July 15, 2002, Eduverse.com, a Nevada corporation now known as "GeneMax Corp." (the "Company"), GeneMax Pharmaceuticals Inc., a Delaware corporation ("GeneMax Pharmaceuticals"), the shareholders of GeneMax Pharmaceuticals (the "GeneMax Shareholders"), and Investor Communications International, Inc., a Washington corporation ("ICI") entered into a share exchange agreement (the "Share Exchange Agreement"). In accordance with the terms of the Share Exchange Agreement and the securities laws of Canada, a Directors' Circular dated July 15, 2002 (the "Directors' Circular") was distributed to certain management, insiders and directors of GeneMax Pharmaceuticals (the "Canadian GeneMax Shareholders"). As of the date of this Form 4, the Company has consummated and finalized the acquisition of GeneMax Pharmaceuticals.

Pursuant to the terms of the Share Exchange Agreement and the Directors' Circular, the Company has acquired from the GeneMax Shareholders up to approximately one hundred percent (100%) of the issued and outstanding shares of common stock of GeneMax Pharmaceuticals. In accordance with the terms of the Share Exchange Agreement, the Directors' Circular and related settlement agreements, the Company was required to issue shares of its restricted common stock as follows: (i) approximately 6,411,304 shares of restricted common stock to the GeneMax Shareholders in proportion to their respective holdings in GeneMax Pharmaceuticals; (ii) approximately 4,479,001 shares of restricted common stock to Canadian GeneMax Shareholders pursuant to the terms of the Directors' Circular; (iii) 181,660 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$0.75 per share for settlement of an aggregate debt in the amount of \$136,245; (iv) 188,154 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$1.00 per share for settlement of an aggregate debt in the amount of \$188,154; and (v) 200,000 shares of restricted common stock to a third party.

As of the date of this Form 4, the Company has issued an aggregate of 11,460,119 shares of its restricted common stock. Certain shares were issued in accordance with the terms and provisions of warrant agreements pursuant to which the holder thereof has the right to convert such warrant into shares of common stock on a one-to-one basis at either the rate of \$0.75 per share or \$1.00 per share. As of the date of this Form 4, there are an aggregate of (i) 277,500 warrants issued and outstanding which may be converted into 277,500 shares of common stock at the rate of \$1.00 per share expiring December 1, 2005; (ii) 175,000 warrants issued and outstanding which may be converted into 175,000 shares of common stock at the rate of \$1.00 per share expiring May 1, 2006; and (iii) 181,660 warrants issued and outstanding which may be converted into 181,660 shares of common stock at the rate of \$0.75 per share expiring May 1, 2006.

An aggregate offering price of \$2,792,976.50 was determined as follows. For purposes of valuation of the shares of common stock issued in accordance with the terms of the Share Exchange Agreement, the aggregate offering price of \$2,204,231.50 was determined as follows: (i) \$8,100.00 for 8,100,000 shares of common stock issued at \$0.001 per share; (ii) \$1,336,482.00 for 2,227,470 shares of common stock issued at \$0.60 per share; (iii) \$82,750.50 for 110,334 shares of common stock issued at \$0.75 per share; (iv) \$452,500.00 for 452,500 shares of common stock issued at \$1.00 per share; (v) \$136,245.00 for 181,660 shares of common stock issued at \$.075 per share pursuant to debt settlement; and (vi) \$188,154.00 for 188,154 shares of common stock issued at \$1.00 per share pursuant to debt settlement. For purposes of valuation of the warrants issued, an aggregate offering price of \$588,745 was determined as follows: (i) \$136,245.00 for 181,660 warrants exercisable into 181,660 shares of common stock at \$0.75 per share; and (ii) \$452,500 for 452,500 warrants exercisable into 452,500 shares of common stock at \$1.00 per share.

The price for the issuance of shares of common stock as reported herein is: (i) \$2,750.00 for the issuance of 2,750,000 shares of common stock at \$0.001 per share to 442668 B.C. Ltd.; and (ii) \$20,465.00 for the issuance of 20,465 shares of common stock at \$1.00 per share to 442668 B.C. Ltd. for settlement of debt.

ATTACHMENT B TO FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FOR WILFRED JEFFERIES

Of the 2,770,465 shares of common stock beneficially owned by Dr. Wilfred Jefferies as reported herein, Dr. Jefferies has sole voting and disposition rights over the 2,770,465 shares of common stock issued of record to 442668 B.C. Ltd.